ARQTHIGH SIGNALFINANCIAL10-K

ARQT demonstrated substantial operational improvement with revenue roughly doubling and operating losses meaningfully reduced, though cash position declined and debt burden increased significantly.

The company appears to be successfully scaling its commercial operations with dramatically improved revenue performance and much narrower operating losses, suggesting the business model is gaining traction. However, the substantial increase in interest expense and decline in cash reserves indicates growing financial leverage that will require careful monitoring.

Comparing 2026-02-25 vs 2025-02-25View on EDGAR →
FINANCIAL ANALYSIS

ARQT showed strong top-line growth with revenue roughly doubling year-over-year, accompanied by substantially narrower operating losses and much improved operating cash flow performance. The balance sheet reflects this growth phase with higher inventory levels and increased current liabilities, though the company's cash position declined materially while total assets expanded. The significant increase in interest expense suggests elevated debt levels are financing this growth trajectory.

FINANCIAL STATEMENT CHANGES
Operating Cash Flow
Cash Flow
+95%
-$112.2M→-$5.6M

Operating cash flow surged 95% — exceptional cash generation, highest quality earnings signal.

Revenue
P&L
+91.3%
$196.5M→$376.1M

Strong top-line growth of 91.3% — accelerating demand or successful expansion into new markets.

Operating Income
P&L
+90.5%
-$128.4M→-$12.2M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Interest Expense
P&L
+89.8%
$15.7M→$29.7M

Interest expense surged 89.8% — significant debt increase or rising rates materially impacting earnings.

Net Income
P&L
+88.5%
-$140.0M→-$16.1M

Net income grew 88.5% — bottom-line growth signals improving overall business health.

Current Liabilities
Balance Sheet
+60.3%
$81.0M→$129.8M

Current liabilities surged 60.3% — significant near-term obligations; verify ability to meet short-term debt.

Inventory
Balance Sheet
+55.8%
$14.5M→$22.6M

Inventory surged 55.8% — growing significantly faster than typical sales pace; potential demand softening or supply chain overcorrection.

Cash & Equivalents
Balance Sheet
-39.9%
$71.3M→$42.9M

Cash declined 39.9% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Total Liabilities
Balance Sheet
+27.3%
$191.3M→$243.5M

Liabilities increased 27.3% — monitor debt-to-equity ratio and interest coverage.

Total Assets
Balance Sheet
+24.1%
$348.9M→$433.0M

Asset base grew 24.1% — expansion through organic growth, acquisitions, or capital deployment.

LANGUAGE CHANGES
NEW — 2026-02-25
PRIOR — 2025-02-25
ADDED
Market f or Registrant's Common Equity, Related Stockholder Matters a nd Issuer Purchases of Equity Securities 88 Item 6.
We have incurred significant losses since our inception, and could continue to incur losses, which, together with our limited history as a commercial-stage company, makes it difficult to assess our future viability; Our capital requirements are difficult to predict and may change.
We may require substantial additional financing to achieve our goals or for strategic purposes, and a failure to obtain this capital if or when needed on acceptable terms, or at all, could force us to delay, limit, reduce, or terminate certain operations, efforts, or strategic initiatives; Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our future operating results to fall below expectations; Our estimated market opportunities are subject to numerous uncertainties and may prove to be inaccurate.
The loss of these manufacturers or their sub-suppliers, their failure or inability to comply with manufacturing or other regulations, or their failure to provide us with sufficient quantities at acceptable quality levels or prices, or at all, would materially and adversely affect our business; We rely on third parties to conduct our nonclinical studies and our clinical trials.
If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may be unable to obtain regulatory approval for our product candidates; Risks related to our intellectual property could materially adversely impact our business, competitive position, financial condition, and results of operations; and Risks related to government regulation of our industry and required approvals could materially adversely impact our business, competitive position, financial condition, and results of operations.
+7 more — sign up free →
REMOVED
Market For Registrant's Common Equity, Related Stockholder Matters And Issuer Purchases Of Equity Securities 97 Item 6.
and Canadian market sales for our products and product candidates, if approved for commercial uses; our commercialization, marketing, and manufacturing capabilities and strategy; the success of competing therapies that are or may become available; our ability to attract and retain key management and technical personnel; our expectations regarding our ability to obtain, maintain, and enforce intellectual property protection for our products and product candidates; and our estimates regarding expenses, future revenue, capital requirements, and needs for additional financing.
We have incurred significant losses since our inception, and could continue to incur losses, which, together with our limited history as a commercial-stage company, makes it difficult to assess our future viability; Due to the recent commercialization of products approved for commercial sale, as well as our development strategy and continued development of our pipeline of product candidates, our capital requirements are difficult to predict and may change.
We may require substantial additional financing to achieve our goals, and a failure to obtain this capital if or when needed on acceptable terms, or at all, could force us to delay, limit, reduce, or terminate certain operations or efforts; Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our future operating results to fall below expectations; Our estimated market opportunities are subject to numerous uncertainties and may prove to be inaccurate.
The loss of these manufacturers or their sub-suppliers, or their failure to provide us with sufficient quantities at acceptable quality levels or prices, or at all, would materially and adversely affect our business; If our third-party manufacturers fail to comply with manufacturing or other regulations, our financial results and financial condition will be adversely affected; We rely on third parties to conduct our nonclinical studies and our clinical trials.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →